$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq

$biorq Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023010973 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q2
Revenue	$2.000K	$14.00K	$863.0K
YoY Change	-99.85%	-96.78%	-95.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.356M	$8.023M	$8.410M
YoY Change	-37.91%	-33.74%	-62.98%
% of Gross Profit
Research & Development	$7.190M	$5.767M	$5.904M
YoY Change	9.64%	-32.03%	-55.94%
% of Gross Profit
Depreciation & Amortization	$100.0K	$158.0K	$200.0K
YoY Change	-66.67%	-57.64%	-60.0%
% of Gross Profit
Operating Expenses	$15.55M	$13.79M	$14.31M
YoY Change	-22.33%	-33.04%	-60.37%
Operating Profit	-$15.54M		-$14.21M
YoY Change	-21.92%		-60.14%
Interest Expense	$2.680M	$2.773M	$2.772M
YoY Change	-2.9%	-105.49%	-20.85%
% of Operating Profit
Other Income/Expense, Net	-$81.00K	-$2.207M	$5.735M
YoY Change	-90.01%	-81.94%	97.69%
Pretax Income	-$17.44M	-$13.21M	-$6.834M
YoY Change	20.37%	-84.07%	-83.49%
Income Tax	$0.00	$259.0K	-$837.0K
% Of Pretax Income
Net Earnings	-$17.40M	-$13.72M	-$5.513M
YoY Change	26.01%	-85.23%	-92.98%
Net Earnings / Revenue	-870000.0%	-98014.29%	-638.82%
Basic Earnings Per Share	-$1.59	-$1.64	-$0.75
Diluted Earnings Per Share	-$1.59	-$1.64	-$29.90K
COMMON SHARES
Basic Shares Outstanding	11.83M	190.4M	184.2M
Diluted Shares Outstanding	10.97M		7.375M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.46M	$30.49M	$48.51M
YoY Change	-54.69%	-65.51%	-26.5%
Cash & Equivalents	$30.50M	$30.50M	$48.50M
Short-Term Investments
Other Short-Term Assets	$309.0K	$565.0K	$1.060M
YoY Change	-73.06%	-49.05%	96.66%
Inventory
Prepaid Expenses	$3.059M	$3.634M	$7.615M
Receivables		$0.00	$0.00
Other Receivables		$828.0K	$817.0K
Total Short-Term Assets	$37.17M	$38.12M	$60.15M
YoY Change	-50.46%	-61.28%	-47.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.498M	$1.654M	$2.454M
YoY Change	-45.37%	-58.77%	-55.17%
Goodwill	$6.072M	$6.072M	$6.072M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$6.000M	$6.000M	$6.000M
YoY Change
Other Assets	$6.259M	$6.201M	$6.227M
YoY Change	1819.94%	1802.15%	4165.07%
Total Long-Term Assets	$16.08M	$15.41M	$16.96M
YoY Change	37.18%	48.02%	201.71%
TOTAL ASSETS
Total Short-Term Assets	$37.17M	$38.12M	$60.15M
Total Long-Term Assets	$16.08M	$15.41M	$16.96M
Total Assets	$53.24M	$53.53M	$77.10M
YoY Change	-38.62%	-50.82%	-35.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.422M	$3.606M	$4.315M
YoY Change	-36.39%	-58.59%	-70.36%
Accrued Expenses	$16.33M	$14.06M	$28.80M
YoY Change	-43.67%	-54.41%	-50.11%
Deferred Revenue	$44.00K	$47.00K	$89.00K
YoY Change	-77.32%	-84.39%	-79.91%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$25.08M	$23.31M	$40.58M
YoY Change	-46.32%	-62.17%	-52.61%
LONG-TERM LIABILITIES
Long-Term Debt	$128.2M	$127.8M	$127.1M
YoY Change	1.14%	1.12%	-19.96%
Other Long-Term Liabilities	$4.973M	$4.696M	$5.537M
YoY Change	-23.04%	-19.23%	-62.48%
Total Long-Term Liabilities	$4.973M	$4.696M	$5.537M
YoY Change	-23.04%	-19.23%	-62.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.08M	$23.31M	$40.58M
Total Long-Term Liabilities	$4.973M	$4.696M	$5.537M
Total Liabilities	$158.2M	$155.8M	$173.2M
YoY Change	-12.05%	-19.61%	-33.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$844.3M	-$826.8M	-$808.0M
YoY Change	5.21%	4.83%	23.91%
Common Stock	$758.4M	$743.6M	$731.0M
YoY Change	4.11%	2.88%	37.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$105.0M	-$102.3M	-$96.11M
YoY Change
Total Liabilities & Shareholders Equity	$53.24M	$53.53M	$77.10M
YoY Change	-38.62%	-50.82%	-35.72%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q2
OPERATING ACTIVITIES
Net Income	-$17.40M	-$13.72M	-$5.513M
YoY Change	26.01%	-85.23%	-92.98%
Depreciation, Depletion And Amortization	$100.0K	$158.0K	$200.0K
YoY Change	-66.67%	-57.64%	-60.0%
Cash From Operating Activities	-$12.10M	-$11.02M	-$19.64M
YoY Change	-49.58%	-72.49%	-44.97%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$72.00K	-$214.0K
YoY Change	-95.32%		-45.13%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$6.000K	-$72.00K	-$214.0K
YoY Change	-98.25%	-134.12%	-61.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.08M	4.516M	1.125M
YoY Change	285.48%	-93.86%	-97.0%
NET CHANGE
Cash From Operating Activities	-12.10M	-11.02M	-19.64M
Cash From Investing Activities	-6.000K	-72.00K	-214.0K
Cash From Financing Activities	12.08M	4.516M	1.125M
Net Change In Cash	-23.00K	-6.574M	-18.73M
YoY Change	-99.89%	-119.5%	-1573.49%
FREE CASH FLOW
Cash From Operating Activities	-$12.10M	-$11.02M	-$19.64M
Capital Expenditures	$16.00K	$72.00K	-$214.0K
Free Cash Flow	-$12.12M	-$11.09M	-$19.43M
YoY Change	-50.23%	-72.31%	-44.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AssetsCurrent
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001580063
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://bioratherapeutics.com/20221231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://bioratherapeutics.com/20221231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Statement Of Income Or Comprehensive Income Extensible Enumeration DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39334
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIORA THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3950390
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4330 La Jolla Village Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2022	dei	City Area Code CityAreaCode	833
CY2022	dei	Local Phone Number LocalPhoneNumber	727-2841
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	BIOR
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	114439824
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11828453
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30486000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88397000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	653000
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	828000
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4199000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7232000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2603000
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2493000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38116000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	98775000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3666000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1482000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6201000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	326000
CY2022Q4	us-gaap	Goodwill Goodwill	6072000
CY2021Q4	us-gaap	Goodwill Goodwill	6072000
CY2022Q4	us-gaap	Assets Assets	53525000
CY2021Q4	us-gaap	Assets Assets	108839000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3606000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8709000
CY2022Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16161000
CY2021Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	34157000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3538000
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	18731000
CY2022Q4	bior	Current Portion Of Capital Lease Obligations CurrentPortionOfCapitalLeaseObligations	0
CY2021Q4	bior	Current Portion Of Capital Lease Obligations CurrentPortionOfCapitalLeaseObligations	12000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23305000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	61609000
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	127811000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	126392000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4696000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5814000
CY2022Q4	us-gaap	Liabilities Liabilities	155812000
CY2021Q4	us-gaap	Liabilities Liabilities	193815000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	164000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	164000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9098844
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7429458
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8928498
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7274889
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	743626000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	722782000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-826843000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-788686000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	170346
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	154569
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	19078000
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	19078000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102287000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-84976000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53525000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108839000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	305000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1247000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24049000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45785000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38037000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73299000
CY2022	us-gaap	Operating Expenses OperatingExpenses	62086000
CY2021	us-gaap	Operating Expenses OperatingExpenses	119084000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-61781000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-117837000
CY2022	us-gaap	Interest Expense InterestExpense	10990000
CY2021	us-gaap	Interest Expense InterestExpense	12636000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20904000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	54157000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2617000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5990000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49250000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-178640000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-420000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-48830000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-178521000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	10673000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-68891000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-247412000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.40
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.40
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-46.42
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-46.42
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	1.40
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	1.40
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-17.91
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-17.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-64.33
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-64.33
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7635107
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7635107
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3846187
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3846187
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-106994000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46554000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	222000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	712000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-722000
CY2021	bior	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	118010000
CY2021	bior	Stock Issued During Period Value Purchase Warrants StockIssuedDuringPeriodValuePurchaseWarrants	42864000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	44607000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	3627000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13556000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-247412000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-84976000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9282000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	98000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-267000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	3929000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7804000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38157000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102287000
CY2022	us-gaap	Profit Loss ProfitLoss	-38157000
CY2021	us-gaap	Profit Loss ProfitLoss	-247412000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	10673000
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-68891000
CY2022	bior	Non Cash Revenue Reserve NonCashRevenueReserve	0
CY2021	bior	Non Cash Revenue Reserve NonCashRevenueReserve	979000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	907000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1437000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7804000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11962000
CY2022	bior	Loss On Extinguishment Of Convertible Notes And Accrued Interest LossOnExtinguishmentOfConvertibleNotesAndAccruedInterest	-2722000
CY2021	bior	Loss On Extinguishment Of Convertible Notes And Accrued Interest LossOnExtinguishmentOfConvertibleNotesAndAccruedInterest	-946000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1419000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1572000
CY2022	bior	Inducement Loss On Convertible Note InducementLossOnConvertibleNote	0
CY2021	bior	Inducement Loss On Convertible Note InducementLossOnConvertibleNote	-11265000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-543000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-99000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	545000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-18365000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20904000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	54157000
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	5731000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	828000
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3387000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1399000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	158000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5072000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8686000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-417000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-22910000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	79000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1720000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4412000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-66175000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-140333000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1758000
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-27153000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64417000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-167486000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	792000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	855000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-792000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-855000
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-387000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-792000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1242000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9014000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46776000
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3318000
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	79448000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	98000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46000000
CY2022	bior	Payments For Insurance Financing PaymentsForInsuranceFinancing	5120000
CY2021	bior	Payments For Insurance Financing PaymentsForInsuranceFinancing	3750000
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1348000
CY2022	bior	Principal Payments On Capital Lease Obligations PrincipalPaymentsOnCapitalLeaseObligations	12000
CY2021	bior	Principal Payments On Capital Lease Obligations PrincipalPaymentsOnCapitalLeaseObligations	295000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7298000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	166831000
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-1782000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7298000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	165049000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57911000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3679000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88397000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92076000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30486000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88397000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5871000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7536000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	31000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	367000
CY2022	bior	Settlement Of Warrant Liability SettlementOfWarrantLiability	0
CY2021	bior	Settlement Of Warrant Liability SettlementOfWarrantLiability	72010000
CY2022	bior	Issuance Of Common Stock In Settlement In Accrued Expenses IssuanceOfCommonStockInSettlementInAccruedExpenses	98000
CY2021	bior	Issuance Of Common Stock In Settlement In Accrued Expenses IssuanceOfCommonStockInSettlementInAccruedExpenses	712000
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	44606000
CY2022	bior	Enumera Molecular Investment In Exchange For Assets EnumeraMolecularInvestmentInExchangeForAssets	6000000
CY2021	bior	Enumera Molecular Investment In Exchange For Assets EnumeraMolecularInvestmentInExchangeForAssets	0
CY2022	bior	Issuance Of Common Stock And Re Priced Warrants Upon Settlement Of Accrued Interest IssuanceOfCommonStockAndRePricedWarrantsUponSettlementOfAccruedInterest	3929000
CY2021	bior	Issuance Of Common Stock And Re Priced Warrants Upon Settlement Of Accrued Interest IssuanceOfCommonStockAndRePricedWarrantsUponSettlementOfAccruedInterest	3627000
CY2022	bior	Issuance Of Warrants Upon Settlement Of Accrued Interest IssuanceOfWarrantsUponSettlementOfAccruedInterest	2300000
CY2021	bior	Issuance Of Warrants Upon Settlement Of Accrued Interest IssuanceOfWarrantsUponSettlementOfAccruedInterest	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2922000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	bior	Change In Fair Value Of Re Priced Equity Classified Warrants ChangeInFairValueOfRePricedEquityClassifiedWarrants	619000
CY2021	bior	Change In Fair Value Of Re Priced Equity Classified Warrants ChangeInFairValueOfRePricedEquityClassifiedWarrants	0
CY2022	bior	Equity Offering Costs Incurred But Not Paid EquityOfferingCostsIncurredButNotPaid	116000
CY2021	bior	Equity Offering Costs Incurred But Not Paid EquityOfferingCostsIncurredButNotPaid	200000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	86000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30500000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-826800000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38200000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64400000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the estimate of variable consideration in connection with the recognition of revenue, the valuation of stock options, the valuation of goodwill, the valuation of the derivative liability associated with the Convertible Notes, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, the valuation of assets held for sale, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Payor Concentration</span></p><div style="font-size:10.0pt;font-family:"Times New Roman", serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company historically relied upon reimbursements from third-party government payors and private-payor insurance companies to collect accounts receivable. As a result of the Strategic Transformation, all revenue from Laboratory Operations has been classified as discontinued operations and there were no significant concentrations as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022. The Company’s significant third-party payors and their related accounts receivable balances and revenues as a percentage of total accounts receivable balances as of December 31, 2021 and of revenues for the year ended December 31, 2021 are as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.986%;"/> <td style="width:1.615%;"/> <td style="width:31.399%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Percentage of Accounts Receivable</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Blue Shield of Texas</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">United Healthcare</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Government Health Benefits Programs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.842%;"/> <td style="width:1.615%;"/> <td style="width:31.543%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Percentage of Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1)</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Year Ended December 31, 2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Blue Shield of Texas</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Aetna</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Cigna</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">United Healthcare</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Government Health Benefits Programs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table><p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:77.778%;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Percentage of revenue table shows amounts as a percentage of total revenue, including revenue classified as discontinued operations. Refer to Note </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> for details of the breakdown of revenue.</span></p></div>
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	15100000
CY2021	bior	Transaction Costs TransactionCosts	1800000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	11848000
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	500000
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Embedded Derivative Related to Convertible Notes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In December 2020, the Company issued Convertible Notes with an embedded derivative that was required to be bifurcated from the host contract and remeasured to fair value at each balance sheet date. Any resulting gain or loss related to the change in the fair value of the embedded derivative was recorded to other income, net in the consolidated statements of operations. As of December 31, 2022, the conversion option has expired and the Company no longer has an embedded derivative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2021	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	59362000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	0
CY2021	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	63741000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	11848000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	600000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	bior	Minimum Percentage Of Recognized Income Tax Positions MinimumPercentageOfRecognizedIncomeTaxPositions	0.50
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0
CY2021	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-4379000
CY2022	bior	Disposal Group Including Discontinued Operation Research And Development Income And Expenses DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentIncomeAndExpenses	0
CY2021	bior	Disposal Group Including Discontinued Operation Research And Development Income And Expenses DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentIncomeAndExpenses	1590000
CY2021	us-gaap	Loss On Contract Termination LossOnContractTermination	19300000
CY2021	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	10900000
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	6000000.0
CY2022	bior	Disposal Group Including Discontinued Operation Selling And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense	0
CY2021	bior	Disposal Group Including Discontinued Operation Selling And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense	38753000
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	1175000
CY2021	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	18247000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1175000
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	58590000
CY2022	bior	Disposal Group Including Discontinued Operation Non Operating Interest Income Expense And Other Income Expense Net DisposalGroupIncludingDiscontinuedOperationNonOperatingInterestIncomeExpenseAndOtherIncomeExpenseNet	0
CY2021	bior	Disposal Group Including Discontinued Operation Non Operating Interest Income Expense And Other Income Expense Net DisposalGroupIncludingDiscontinuedOperationNonOperatingInterestIncomeExpenseAndOtherIncomeExpenseNet	-5922000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	10673000
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-68891000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2000000.0
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6600000
CY2021	us-gaap	Revenues Revenues	60609000
CY2022	us-gaap	Revenues Revenues	12153000
CY2021	us-gaap	Revenues Revenues	60609000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3634000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6123000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	565000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1109000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4199000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7232000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5653000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9287000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3999000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5621000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3666000
CY2022	us-gaap	Depreciation Depreciation	900000
CY2021	us-gaap	Depreciation Depreciation	1400000
CY2022Q4	bior	Accrual For Reimbursement Claims And Settlements Net Of Current Portion AccrualForReimbursementClaimsAndSettlementsNetOfCurrentPortion	0
CY2021Q4	bior	Accrual For Reimbursement Claims And Settlements Net Of Current Portion AccrualForReimbursementClaimsAndSettlementsNetOfCurrentPortion	192000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	601000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	4095000
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	201000
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	326000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6201000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	326000
CY2020Q4	bior	Goodwill In Assets Held For Sale And Long Term Asset GoodwillInAssetsHeldForSaleAndLongTermAsset	6219000
CY2021	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	147000
CY2022Q4	us-gaap	Goodwill Goodwill	6072000
CY2021Q4	us-gaap	Goodwill Goodwill	6072000
CY2022Q4	bior	Accrual For Reimbursement Claims And Settlements Current AccrualForReimbursementClaimsAndSettlementsCurrent	8372000
CY2021Q4	bior	Accrual For Reimbursement Claims And Settlements Current AccrualForReimbursementClaimsAndSettlementsCurrent	18127000
CY2022Q4	bior	Commission And Bonus Current CommissionAndBonusCurrent	1433000
CY2021Q4	bior	Commission And Bonus Current CommissionAndBonusCurrent	3883000
CY2022Q4	bior	Vacation And Payroll Benefits Current VacationAndPayrollBenefitsCurrent	1724000
CY2021Q4	bior	Vacation And Payroll Benefits Current VacationAndPayrollBenefitsCurrent	6894000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	307000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	652000
CY2022Q4	bior	Accrued Interest Current AccruedInterestCurrent	890000
CY2021Q4	bior	Accrued Interest Current AccruedInterestCurrent	802000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	893000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	445000
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	489000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	301000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2050000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3009000
CY2022Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16161000
CY2021Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	34157000
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	5622000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4696000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5814000
CY2022Q4	bior	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2021Q4	bior	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2021Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0
CY2022Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	127800000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	126400000
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	71800000
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	86600000
CY2021Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4900000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6300000
CY2021Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	20200000
CY2021Q4	us-gaap	Deferred Sales Inducement Cost Impairment Loss DeferredSalesInducementCostImpairmentLoss	9800000
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	173477
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	900000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1500000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	900000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	600000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1500000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5100000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	965000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	235000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	209000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	215000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	18000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1642000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	148000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1494000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2141000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1086000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	237000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	208000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	251000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3923000
CY2020Q3	bior	Number Of States Participating In Settlement NumberOfStatesParticipatingInSettlement	45
CY2021Q3	bior	Aggregate Amount Of Historical Payments AggregateAmountOfHistoricalPayments	5700000
CY2021Q4	bior	Aggregate Amount Of Historical Payments AggregateAmountOfHistoricalPayments	3300000
CY2022	bior	Claim Settlement Amount Refunded ClaimSettlementAmountRefunded	11000000
CY2020Q4	bior	Aggregate Amount Of Historical Payments AggregateAmountOfHistoricalPayments	27400000
CY2022Q4	bior	Payor Recoupment PayorRecoupment	1100000
CY2020Q4	bior	Number Of Actions Pending NumberOfActionsPending	2
CY2020Q4	bior	Number Of Actions Pending NumberOfActionsPending	2
CY2021Q1	bior	Warrants And Common Stock Issuance Cost WarrantsAndCommonStockIssuanceCost	1400000
CY2022	bior	Warrants Issuance Cost WarrantsIssuanceCost	500000
CY2022	bior	Common Stock Issuance Cost CommonStockIssuanceCost	900000
CY2021Q1	bior	Remeasurement Of Warrant Liability RemeasurementOfWarrantLiability	10200000
CY2021Q1	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2600000
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20000
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2021Q2	bior	Warrants And Common Stock Issuance Cost WarrantsAndCommonStockIssuanceCost	2100000
CY2021Q2	bior	Warrants Issuance Cost WarrantsIssuanceCost	700000
CY2021Q2	bior	Common Stock Issuance Cost CommonStockIssuanceCost	1400000
CY2021Q2	bior	Remeasurement Of Warrant Liability RemeasurementOfWarrantLiability	31800000
CY2021Q2	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-5100000
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	41800000
CY2021Q3	bior	Warrants And Common Stock Issuance Cost WarrantsAndCommonStockIssuanceCost	2800000
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	77280
CY2021Q3	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3400000
CY2021Q3	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1900000
CY2021Q4	bior	Remeasurement Of Warrant Liability RemeasurementOfWarrantLiability	18700000
CY2021	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-6700000
CY2022Q4	bior	Remeasurement Of Warrant Liability RemeasurementOfWarrantLiability	500000
CY2022	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	18200000
CY2021	bior	Common Stock Issued Upon Exercise Of Warrants CommonStockIssuedUponExerciseOfWarrants	1147365
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	25.00
CY2021Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18700000
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000000.0
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	6000000.0
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1600000
CY2022Q4	bior	Warrants And Common Stock Issuance Cost WarrantsAndCommonStockIssuanceCost	800000
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	900000
CY2022Q4	bior	Number Of Vote Per Preferred Stock Held NumberOfVotePerPreferredStockHeld	3000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	344713
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	118.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	357798
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.90
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	119954
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	110.67
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	582557
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.89
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	582557
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	59.89
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	164576
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	113.99
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y2M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.020
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.042
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.907
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.013
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.529
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.770
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.09
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	53.28
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	2978000
CY2022	bior	Income Tax Reconciliation Convertible Debt IncomeTaxReconciliationConvertibleDebt	-4390000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7804000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13556000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	10500000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M25D
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-546000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-347000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	126000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-767000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	347000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-119000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	347000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-119000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-420000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10343000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-37514000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0
CY2021	bior	Income Tax Reconciliation Convertible Debt IncomeTaxReconciliationConvertibleDebt	12225000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1504000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1700000
CY2022	bior	Effective Income Tax Rate Reconciliation Tax Refunds EffectiveIncomeTaxRateReconciliationTaxRefunds	-900000
CY2021	bior	Effective Income Tax Rate Reconciliation Tax Refunds EffectiveIncomeTaxRateReconciliationTaxRefunds	0
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13004000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18211000
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	705000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	2281000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-420000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	137149000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	124230000
CY2022Q4	bior	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	4027000
CY2021Q4	bior	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	949000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	3454000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1571000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	527000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1447000
CY2022Q4	bior	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	343000
CY2021Q4	bior	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2591000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2603000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	101000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	112000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	145687000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	133417000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	726000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	864000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1201000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	0
CY2022Q4	bior	Deferred Tax Liabilities Investment In Enumera DeferredTaxLiabilitiesInvestmentInEnumera	1317000
CY2021Q4	bior	Deferred Tax Liabilities Investment In Enumera DeferredTaxLiabilitiesInvestmentInEnumera	0
CY2022Q4	bior	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	340000
CY2021Q4	bior	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	743000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1123000
CY2022Q4	bior	Deferred Tax Liabilities Adoption Of Accounting Standard DeferredTaxLiabilitiesAdoptionOfAccountingStandard	0
CY2021Q4	bior	Deferred Tax Liabilities Adoption Of Accounting Standard DeferredTaxLiabilitiesAdoptionOfAccountingStandard	1341000
CY2022Q4	bior	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	552000
CY2021Q4	bior	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	677000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	33000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4879000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4038000
CY2022Q4	bior	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	140808000
CY2021Q4	bior	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	129379000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141155000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129379000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	347000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11800000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	504900000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	246300000
CY2022Q4	bior	Percentage Of Taxable Income Use Of Federal Net Operating Loss Carry Forwards PercentageOfTaxableIncomeUseOfFederalNetOperatingLossCarryForwards	0.80
CY2022	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4815813
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3170765
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	500000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2400000
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	80000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	107000
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-13469000
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14874000
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5997000
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14490000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-253000
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	9760000
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	484000
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	682000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-13722000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5114000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5513000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13808000
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.64
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	435000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	182000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	463000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	167000
CY2021Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-82787000
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-36874000
CY2021Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-41400000
CY2021Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-17460000
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-10087000
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6870000
CY2021Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-37131000
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-14803000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-92874000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-43744000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-78531000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-32263000
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.98
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.98
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.41
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.41
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-30.70
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-30.70
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.03
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.03
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
bior-20221231_def.xml	Edgar Link	unprocessable
bior-20221231_cal.xml	Edgar Link	unprocessable
0000950170-23-010973-index-headers.html	Edgar Link	pending
0000950170-23-010973-index.html	Edgar Link	pending
0000950170-23-010973.txt	Edgar Link	pending
0000950170-23-010973-xbrl.zip	Edgar Link	pending
bior-20221231.htm	Edgar Link	pending
bior-20221231.xsd	Edgar Link	pending
bior-ex10_2.htm	Edgar Link	pending
bior-ex10_3.htm	Edgar Link	pending
bior-ex10_4.htm	Edgar Link	pending
bior-ex10_5.htm	Edgar Link	pending
bior-ex10_6.htm	Edgar Link	pending
bior-ex10_7.htm	Edgar Link	pending
bior-ex10_8.htm	Edgar Link	pending
bior-ex10_9.htm	Edgar Link	pending
bior-ex21_1.htm	Edgar Link	pending
bior-ex23_1.htm	Edgar Link	pending
bior-ex31_1.htm	Edgar Link	pending
bior-ex31_2.htm	Edgar Link	pending
bior-ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img188384320_0.jpg	Edgar Link	pending
img188384320_1.jpg	Edgar Link	pending
img188384320_2.jpg	Edgar Link	pending
img188384320_3.jpg	Edgar Link	pending
img188384320_4.jpg	Edgar Link	pending
img188384320_5.jpg	Edgar Link	pending
img188384320_6.jpg	Edgar Link	pending
img188384320_7.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
bior-20221231_pre.xml	Edgar Link	unprocessable
bior-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bior-20221231_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq

2023 Q1 Form 10-K Financial Statement

#000095017023010973 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIORQ BIORA THERAPEUTICS, INC. Stock $biorq

2023 Q1 Form 10-K Financial Statement

#000095017023010973 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq